In this issue:
Enzalutamide + standard first-line therapy in metastatic prostate cancer
Apalutamide for metastatic, castration-sensitive prostate cancer
Validation of IMPROD biparametric MRI for prostate cancer
Enzalutamide + ADT in metastatic hormone-sensitive prostate cancer
Pelvic lymph nodes in radiation fields
mpMRI for predicting prostate cancer pathology and tumour staging
UK regional variation in survival quality
RNA splicing of BHC80 gene in neuroendocrine prostate cancer
Stereotactic ablative radiotherapy for oligometastatic tumours
Aerobic recovery following radical prostatectomy
Please login below to download this issue (PDF)